The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
Five candidates are now in phase III trials in the West, as Pfizer approaches its first interim readout.
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
The FDA’s emergency use authorisation for plasma for Covid-19 looks questionable. If this presages an early vaccine nod, we should be very afraid.
Valrox leaves a disproportionate hole in Biomarin’s valuation, but gene therapy competitors shouldn’t celebrate just yet.
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.